期刊
JOURNAL OF NEUROSURGERY
卷 104, 期 4, 页码 583-592出版社
AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/jns.2006.104.4.583
关键词
survivin gene; tumor-specific promoter; transcriptional targeting; adenoviral vector; conditionally replicative adenovirus
资金
- NCI NIH HHS [R01 CA83821] Funding Source: Medline
- NICHD NIH HHS [K12 HD01261-02] Funding Source: Medline
- NIDDK NIH HHS [R01 DK063615-01] Funding Source: Medline
Object. Malignant brain tumors have been proved to be resistant to standard treatments and therefore require new therapeutic strategies. Survivin, a recently described member of the inhibitor of apoptosis protein family, is overexpressed in several human brain tumors, primarily gliomas, but is downregulated in normal tissues. The authors hypothesized that the expression of tumor-specific survivin could be exploited for treatment of gliomas. by targeting the tumors with gene therapy vectors. Methods. Following confirmation of survivin expression in glioma cell lines, an adenoviral vector containing the survivin promoter and the reporter gene luciferase was tested in established and primary glioma cells, normal astrocytic cells, and normal human brain tissues. High levels of reporter gene expression were observed in established tumor and primary tumor cell lines and low levels of expression in astrocytes and normal human brain tissue. To test oncolytic potency, the authors constructed survivin promoter-based conditionally replicative adenoviruses (CRAds), composed of survivin promoter-regulated El gene expression and an RGD-4C capsid modification. These CRAds could efficiently replicate within and kill a variety of established glioma tumor cells, but were inactive in a normal human liver organ culture. Finally, survivin promoter-based CRAds significantly inhibited the growth of glioma xenografts in vivo. Conclusions. Together these data indicate that the survivin promoter is a promising tumor-specific promoter for transcriptional targeting of adenovirus-based vectors and CRAds for malignant gliomas. The strategy of using survivin-CRAds may thug translate into an experimental therapeutic approach that can be used in human clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据